PPARgamma2 gene expression signature in U-33 / gamma2 and U-33/c mouse cell lines
Description
Murine marrow-derived U-33 cells represent a clonal cell line spontaneously immortalized in the long term bone marrow culture conditions.
To study the effect of PPARgamma2 on marrow mesenchymal stem cell (MSC) differentiation, U-33 cells were stably transfected with either the PPARgamma2 expression construct (U-33/gamma2 cells) or an empty vector control (U-33/c cells). The effect of PPARgamma2 on MSC molecular signature was evaluated with respect to the expression of 135 genes that represent markers of either early or lineage committed stem cells. For further details see the supporting manuscript (Shockley et al., 2007).
To compliment biochemical analyses, rosiglitazone treatment (1 µM) of a marrow stromal cell line (UAMS-33) transfected with empty vector (U-33/c) or with PPARgamma2 (U-33/gamma2) were analyzed by microarray. The effect of Rosi stimulated PPARgamma2 on genes related to the insulin-like growth factor system was studied further. For more details see Lecka-Czernik et al., 2006.
In order to identify mechanisms by which PPARgamma2 suppresses osteoblastogenesis and promotes adipogenesis in MSC, we analyzed the PPARgamma2 transcriptome in response to Rosi. The experimental design consisted of 2 levels of rosiglitazone treatment (with/without Rosi), 3 time points (2-, 24- and 72-hr after treatment) in both cell types (U-33/g2 and U-33/c cells). For further details see the supporting manuscript (Shockley et al., 2009)
Data
- README file for Shockley et al. 2007
- Microarray design file for Shockley et al. 2007
- README file for Lecka-Czernik et al. 2007
- Microarray Design file for Lecka-Czernik et al. 2007
- README file for Shockley et al. 2009
- Microarray Design file for Shockley et al. 2009
- 24 AR 8-20-04.CEL
- 24 AV 8-20-04.CEL
- 24 DR 8-20-04.CEL
- 24 DV 8-20-04.CEL
- 72 AR 8-20-04.CEL
- 72 AV 8-20-04.CEL
- 72 DR 8-20-04.CEL
- 72 DV 8-20-04.CEL
- ADO 86-2-ER 10-15-04.CEL
- ADO 86-2-EV 10-15-04.CEL
- ADO 86-2-FR 10-15-04.CEL
- ADO 86-2-FV 10-15-04.CEL
- ADO 86-2-GR 10-15-04.CEL
- ADO 86-2-GV 10-15-04.CEL
- ADO 86-2-HR 10-15-04.CEL
- ADO 86-2-HV 10-15-04.CEL
- REM 24 BR 6-09-04.CEL
- REM 24 BV 6-09-04.CEL
- REM 24 CR 6-09-04.CEL
- REM 24 CV 6-09-04.CEL
- REM 72 BR 6-09-04.CEL
- REM 72 BV 6-09-04.CEL
- REM 72 CR 6-09-04.CEL
- REM 72 CV 6-09-04.CEL
Publications
Shockley KR, Lazarenko OP, Czernik PJ, Rosen CJ, Churchill GA, Lecka-Czernik B
J Cell Biochem. 2009 Feb 1;106(2):232-46 [ Full Text ] PMCID: PMC2745312
Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, Rosen CJ
Endocrinology. 2007 Feb;148(2):903-11 [ Full Text ] PMCID: PMC1851001
Shockley KR, Rosen CJ, Churchill GA, Lecka-Czernik B
PPAR Res. 2007;2007:81219 [ Full Text ] PMCID: PMC2234088
